Klaus Kutz Selected Research

BBR 3576

1/2004

Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Klaus Kutz Research Topics

Disease

1	Asthma (Bronchial Asthma) 09/2015
1	Neoplasms (Cancer) 01/2004
1	Neutropenia 01/2004
1	Cardiotoxicity 01/2004

Drug/Important Bio-Agent (IBA)

1	Messenger RNA (mRNA)IBA 09/2015
1	Catalytic DNA (Deoxyribozyme)IBA 09/2015
1	Pharmaceutical PreparationsIBA 01/2004
1	acivicin (AT 125)IBA 01/2004
1	anthrapyrazoleIBA 01/2004
1	BBR 3576IBA 01/2004